Maxime Verhoeven

175 Utility of the HandScan in monitoring disease activity in RA Table 1 (continued) All n= 64 Early n= 32 Established n= 32 p-value Treatment response ∆DAS28 month 3, mean (SD) 1.5 (1.3) 2.0 (1.0) 0.9 (1.3) <0.01* ∆DAS28 month 6, mean (SD) 1.9 (1.3) 2.5 (1.0) 1.1 (1.1) <0.01* ∆OST-score month 3, mean (SD) 1.6 (4.6) 2.6 (4.7) 0.5 (4.3) 0.04 ∆OST-score month 6, mean (SD) 1.7 (5.3) 2.6 (5.9) 0.7 (4.6) 0.10 EULAR good response month 3, n (%) 27 (42) 19 (59) 8 (25) <0.01* EULAR good response month 6, n (%) 34 (53) 28 (88) 6 (19) <0.01* ACR50 response month 3, n (%) 20 (31) 14 (44) 6 (19) 0.03* ACR50 response month 6, n (%) 28 (44) 18 (56) 10 (31) 0.04* ∆HAQ score month 3, median (IQR) 0.3 (0.0 – 0.8) 0.4 (0.1 – 0.8) 0.3 (0.0 – 0.8) 0.35 ∆HAQ score month 6, median (IQR) 0.5 (0.3 – 0.9) 0.6 (0.3 – 1.0) 0.4 (0.1 – 0.9) 0.24 All= early and established rheumatoid arthritis (RA) patients; Early= newly diagnosed RA patients starting conventional synthetic DMARD therapy; Established= established RA patients starting (first of new) TNF inhibitor as additional therapy. BMI= body mass index; SD= standard deviation; RA= rheumatoid arthritis; RF= rheumatoid factor; CCP= cyclic citrullinated peptide; DAS28= disease activity score assessing 28 joints; SJC28= swollen joint count assessing 28 joints; IQR= interquartile range; TJC28= tender joint count assessing 28 joints; VAS= visual analogue scale, range 0-100=worst; OST= optical spectral transmission, range 0-66=worst; HAQ= Health Assessment Questionnaire, range 0-3=worst. *= statistically significant; **=6 missing. Figure 1 Disease activity measures, functional ability and quality of life over time.* *means for DAS28 and OST-score and medians for SJC, TJC, HAQ and EQ5D-5L DAS28= disease activity score assessing 28 joints; OST-score= optical spectral transmission score; SJC= swollen joint count; TJC= tender joint count; HAQ= health assessment questionnaire; EQ5D- 5L= EuroQol five dimensions questionnaire. 9